Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Synthetic glucagon antagonists and partial agonists.

C Zechel1, D Trivedi, V J Hruby

  • 1Department of Chemistry, University of Arizona, Tucson.

International Journal of Peptide and Protein Research
|August 1, 1991
PubMed
Summary

Researchers synthesized six new glucagon analogues with N-terminal modifications to study their biological activities. Most analogues acted as potent glucagon antagonists, inhibiting adenylate cyclase activity and offering potential for new therapeutic strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An international 20 country patient and physician survey of the usability and acceptability of Stepped Care pathway in Parkinson's disease.

Scientific reports·2025
Same author

"I used their criticisms as my weapon to succeed" Experiences in the dual learning environment of Black, Asian, and ethnically diverse therapeutic radiographer undergraduate students - results of a UK survey.

Radiography (London, England : 1995)·2024
Same author

A randomised controlled trial of energetic activity for depression in young people (READY): a multi-site feasibility trial protocol.

Pilot and feasibility studies·2021
Same author

Responsiveness of stem-like human glioma cells to all-trans retinoic acid and requirement of retinoic acid receptor isotypes α, β and γ.

Neuroscience·2014
Same author

Human dermis-derived cells demonstrate strong features of controlled mesodermal differentiation.

Journal of stem cells & regenerative medicine·2014
Same author

Human dermis-derived cells demonstrate strong features of controlled mesodermal differentiation.

Journal of stem cells & regenerative medicine·2014

Area of Science:

  • Endocrinology and Metabolism
  • Medicinal Chemistry
  • Molecular Pharmacology

Background:

  • Glucagon is a key hormone regulating blood glucose homeostasis.
  • Modifications to the glucagon sequence have previously yielded superagonists and antagonists with altered receptor binding affinities.
  • Understanding structure-activity relationships is crucial for developing targeted glucagon receptor modulators.

Purpose of the Study:

  • To synthesize and characterize novel glucagon analogues with N-terminal and C-terminal modifications.
  • To evaluate the biological activities, including receptor binding and adenylate cyclase modulation, of these new analogues.
  • To explore the potential of these analogues as therapeutic agents targeting the glucagon receptor.

Main Methods:

  • Synthesis of six novel glucagon analogues incorporating unnatural amino acids (Tip, dHis) and sequence deletions (des-Phe6).

Related Experiment Videos

  • Assessment of binding potencies relative to native glucagon using competition assays.
  • Evaluation of adenylate cyclase (AC) stimulation and antagonism in vitro.

    • Main Results:

    • Analogue 2 ([Tip1, Lys17,18,Glu21]glucagon) exhibited partial agonism with reduced AC stimulation (15% max) and 8.9% potency of glucagon.
    • Analogues 3-7 ([Tip1,D-Phe4,Tyr5,Arg12,Lys17,18,Glu21]glucagon, [dHis1,D-Phe4,Tyr5,Arg12,Lys17,18,Glu21]glucagon, etc.) acted as potent glucagon antagonists, showing no AC activation even at high concentrations.
    • Competition experiments confirmed the antagonist activity of analogues 3-7, evidenced by a rightward shift in glucagon-stimulated AC dose-response curves.

    Conclusions:

    • N-terminal modifications, particularly with Tip and dHis residues, combined with C-terminal changes, can yield potent glucagon receptor antagonists.
    • The synthesized analogues provide valuable tools for studying glucagon receptor pharmacology.
    • These novel antagonists hold promise for therapeutic applications in conditions involving dysregulated glucagon signaling.